Methotrexate, blood pressure and arterial function in rheumatoid arthritis: study protocol

Area of Science:

• Rheumatology
• Cardiovascular Medicine
• Pharmacology

Background:

• Inflammation and immune activation are linked to atherosclerosis.
• Methotrexate (MTX), a disease-modifying antirheumatic drug (DMARD), is associated with reduced cardiovascular risk in rheumatoid arthritis (RA).
• Observational studies suggest MTX may lower blood pressure, a key factor in cardiovascular disease.

Purpose of the Study:

• To investigate the temporal effects of MTX on blood pressure and arterial function in RA patients.
• To evaluate MTX as a potential atheroprotective agent.
• To explore the repurposing of MTX for cardiovascular prevention.

Main Methods:

• An intervention comparison study design.
• Focus on measuring blood pressure and surrogate markers of atherosclerosis.
• Involves patients with rheumatoid arthritis.

Main Results:

• Observational data indicates MTX is linked to lower cardiovascular morbidity and mortality in RA.
• Potential mechanism involves MTX's blood pressure-lowering effect.
• This study aims to confirm these effects through intervention.

Conclusions:

• MTX's potential cardiovascular benefits warrant further investigation.
• Repurposing MTX for cardiovascular prevention in RA and other autoimmune disorders is a possibility.
• This study design provides a framework for evaluating MTX's atheroprotective role.